Cantor Fitzgerald Predicts SI-BONE FY2026 Earnings

SI-BONE, Inc. (NASDAQ:SIBN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of SI-BONE in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings of ($0.10) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for SI-BONE's current full-year earnings is ($0.78) per share.

Other research analysts also recently issued reports about the company. Truist Financial increased their price objective on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th.

SI-BONE Price Performance

NASDAQ SIBN traded down $0.84 during mid-day trading on Wednesday, hitting $17.42. The stock had a trading volume of 1,592,400 shares, compared to its average volume of 388,793. The firm's 50 day moving average is $16.59 and its 200 day moving average is $15.74. SI-BONE has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The stock has a market capitalization of $742.35 million, a price-to-earnings ratio of -18.93 and a beta of 0.94.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million.

Hedge Funds Weigh In On SI-BONE

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. boosted its stake in shares of SI-BONE by 11.1% in the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company's stock valued at $37,072,000 after buying an additional 264,254 shares during the period. Vanguard Group Inc. lifted its stake in SI-BONE by 1.5% during the first quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company's stock worth $34,292,000 after purchasing an additional 35,349 shares during the last quarter. Silvercrest Asset Management Group LLC increased its position in SI-BONE by 21.9% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock worth $27,392,000 after buying an additional 350,970 shares during the period. First Light Asset Management LLC increased its position in SI-BONE by 41.8% during the first quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company's stock worth $22,622,000 after buying an additional 475,426 shares during the period. Finally, Paradigm Capital Management Inc. NY increased its position in SI-BONE by 5.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company's stock worth $19,432,000 after buying an additional 69,831 shares during the period. Hedge funds and other institutional investors own 98.11% of the company's stock.

Insiders Place Their Bets

In related news, CEO Laura Francis sold 38,504 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total transaction of $661,498.72. Following the completion of the sale, the chief executive officer now directly owns 302,958 shares of the company's stock, valued at approximately $5,204,818.44. This trade represents a 11.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the transaction, the senior vice president now owns 244,878 shares of the company's stock, valued at $3,462,574.92. This trade represents a 1.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 95,942 shares of company stock valued at $1,734,203 in the last three months. 4.00% of the stock is currently owned by insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.